U.K. industry reiterates Brexit concerns
The Association of the British Pharmaceutical Industry (ABPI) highlighted that its primary concerns around a "no-deal" Brexit include the continuity of the pharmaceutical supply chain and sharing of data between the U.K. and European regulatory authorities. The bodies have yet to agree on specifics of a long-term cooperation regarding the regulation, trade and supply of medicines following U.K's exit from the union.
In oral testimony before the U.K. Parliament's Exiting the European Union...
Read the full 342 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
$50 USD
